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Antisense oligonucleotides are powerful tools for the in vivo regulation of gene expres-
sion. We have characterized the intracellular distribution of fluorescently tagged phos-
phorothioate oligodeoxynucleotides (PS-ONs) at high resolution under conditions in
which PS-ONs have the potential to display antisense activity. Under these conditions
PS-ONs predominantly localized to the cell nucleus where they accumulated in 20–30
bright spherical foci designated phosphorothioate bodies (PS bodies), which were set
against a diffuse nucleoplasmic population excluding nucleoli. PS bodies are nuclear
structures that formed in cells after PS-ON delivery by transfection agents or microin-
jection but were observed irrespectively of antisense activity or sequence. Ultrastructur-
ally, PS bodies corresponded to electron-dense structures of 150–300 nm diameter and
resembled nuclear bodies that were found with lower frequency in cells lacking PS-ONs.
The environment of a living cell was required for the de novo formation of PS bodies,
which occurred within minutes after the introduction of PS-ONs. PS bodies were stable
entities that underwent noticeable reorganization only during mitosis. Upon exit from
mitosis, PS bodies were assembled de novo from diffuse PS-ON pools in the daughter
nuclei. In situ fractionation demonstrated an association of PS-ONs with the nuclear
matrix. Taken together, our data provide evidence for the formation of a nuclear body in
cells after introduction of phosphorothioate oligodeoxynucleotides.
INTRODUCTION
The modulation of gene expression by antisense oli-
gonucleotides is emerging as a promising new concept
for treatment of human diseases (Sharma and Naray-
anan, 1995; Agrawal, 1996; Crooke and Bennett, 1996).
In addition, antisense molecules prove to be a valuable
tool in basic research applications (e.g., Coats et al.,
1996; Luger et al., 1996). Antisense oligonucleotides are
short polymers comprised of 10–25 modified DNA or
RNA nucleotides that are complementary to se-
quences in their target RNA. Their hybridization to
the target sequence is proposed to interfere with
RNA intermediary metabolism and/or to induce
RNA degradation, resulting in a decreased expres-
sion of the target gene (for review see Crooke, 1996).
So far, the lead chemistry for antisense oligonucle-
otides has been the phosphorothioate modification
in which a nonbridging oxygen atom in the phos-
phate backbone is replaced by sulfur. The focus on
this modification is due to its acceptable properties
in terms of stability, uptake, selectivity, toxicology,
and the support of ribonuclease (RNase) H activity
(Crooke, 1997). Furthermore, these compounds can
be easily and cost-effectively synthesized in bulk
quantities. As a consequence, several phosphoro-
thioate oligodeoxynucleotides (PS-ONs) have en-
tered clinical trials (Dean et al., 1996a; Wagner and
Flanagan, 1997; Webb et al., 1997). Because of its
usefulness, this modification is also being used in
the next generation of antisense drugs, in mixed-
type compounds (Agrawal and Iyer, 1995).
The specific action of antisense oligonucleotides has
been shown numerous times under well-controlled
conditions in cell culture systems as well as in animal
models (e.g., Chiang et al., 1991; Wagner et al., 1993;
Dean and McKay, 1994; Dean et al., 1996b; Monia et al.,‡ Corresponding author.
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1996; Neurath et al., 1996; Wagner et al., 1996; Bennett
et al., 1997). However, little is currently known about
how and where within cells the antisense molecules
bind to their target RNA and exert their activity. Only
in a few cases has more than circumstantial evidence
been provided for their mechanism of action: a RNase
H-dependent degradation of the target RNA was most
convincingly shown in Xenopus oocytes (Shuttleworth
and Colman, 1988) and in a reversibly permeabilized
cell system (Giles et al., 1995). In another case, a PS-ON
led to cleavage of its endogenous target RNA and at
the same time inhibited splicing of a particular intron
(Condon and Bennett, 1996).
It is thought that PS-ONs enter the cell through
endocytotic mechanisms (Beltinger et al., 1995; Tarra-
son et al., 1995, and references therein). It is of key
importance for antisense oligonucleotides to then es-
cape the endosomal/lysosomal compartments into the
cytoplasm. In many reports antisense activity was de-
pendent on the delivery of PS-ONs in complex with a
transfection agent that promotes the escape from ve-
sicular trapping (e.g., Bennett et al., 1992; Wagner et al.,
1993). However, in other reports a transfection agent
was not necessary to achieve specific antisense activity
(e.g., Offensperger et al., 1993; Nestle et al., 1994;
Neurath et al., 1996). These differences may be related
to differences in cell type as well as experimental
protocol but are at this time unresolved. In vivo, trans-
fection agents also do not seem to be a prerequisite for
efficient antisense activity (e.g, Offensperger et al.,
1993; Dean and McKay, 1994; Monia et al., 1996;
Neurath et al., 1996). In many cases, whenever signif-
icant antisense activity was displayed a significant, if
not predominant, fraction of the PS-ONs localized to
the nucleus. A nuclear localization was also predom-
inant shortly after microinjection of PS-ONs into the
cytoplasm (Chin et al., 1990; Leonetti et al., 1991; Fisher
et al., 1993; Wagner et al., 1993). Thus, the nucleus has
been especially implicated as an important site for the
action of antisense PS-ONs. That antisense activity can
indeed occur in the nucleus is clear from work in
which treatment with an antisense PS-ON resulted in
the appearance of an aberrant RNA species in the
nucleus (Condon and Bennett, 1996) and from an ex-
ample in which the target RNA sequences only existed
in the nucleus (intron sequences; Wagner et al., 1993).
On the other hand, antisense oligonucleotides cer-
tainly are also able to act in the cytoplasm, e.g., by
inhibiting the formation of a translation initiation
complex (Baker et al., 1997).
In the present report we characterized at high reso-
lution the spatial and temporal distribution of PS-ONs
in the nucleus under conditions in which they have
the potential to display specific antisense activity. We
find that the introduction of PS-ONs into cells leads to
the formation of nuclear bodies.
MATERIALS AND METHODS
Cell Culture, Observation of Living Cells, and
Induction of Intercellular Adhesion Molecule
(ICAM)-1 Expression
HeLa cells were grown on glass coverslips at 10% CO2 and 37°C in
high glucose, HEPES-buffered DMEM (Life Technologies, Gaithers-
burg, MD) supplemented with 10% FBS (Hyclone, Logan, UT) and
50 U/ml penicillin and 0.1 mg/ml streptomycin.
For observation of living cells, HeLa cells were grown on special
coverslips fitting into a FCS2 live-cell microscopy chamber
(Bioptechs, Butler, PA). After administration of the oligonucleotides
as described below, the chamber was assembled and mounted on a
Zeiss Axiovert 405 fluorescence microscope (Carl Zeiss, Thorn-
wood, NY). The temperature was kept constant at 37°C, and fresh
medium was pumped in every 2 h. Images were acquired with a
Photometrics Nu200 cooled CCD camera (1,320 3 1,035 array,
6.7-mm pixel size, Photometrics, Tucson, AR).
To induce ICAM-1 expression, HeLa cells were treated with 10
ng/ml recombinant tumor necrosis factor-a (TNF-a, RD Systems,
Minneapolis, MN) for 18 h after the delivery of oligonucleotides.
Oligonucleotides
All oligonucleotides employed in the present study are fully mod-
ified phosphorothioate oligodeoxynucleotides. 4298-F is a 18-mer of
the sequence 59-TGGGAGCCATAGCGAGGC-39 and conjugated at
its 59-end to fluorescein. It is complementary to sequences 28 to 110
of the translational start region of human ICAM-1, and its parent
molecule without fluorescent tag has been shown to have specific
antisense activity (Chiang et al., 1991). 12182-T, a 59-Texas Red–
conjugated 20-mer of the sequence 59-CTTCAGAGCGCTC-
CAGCTCT-39 targets exon 5 of rat b-tropomyosin and has specific
antisense activity in a microinjection assay (our unpublished re-
sults). 11068-F is a 20-mer of the sequence 59-TGCATCCCCCAG-
GCCACCAT-39, harbors a 59-end fluorescein, and targets the 39-
untranslated region of murine ICAM-1 (Stepkowski et al., 1994).
11721-F is a 59-fluorescein–conjugated 20-mer of the sequence 59-
TTCCCCAGATGCACCTGTTT-39 and targets the 39-untranslated
region of human E-selectin. This PS-ON has antisense activity
against E-selectin but shows no effect on ICAM-1 expression (Ben-
nett et al., 1994) and therefore is employed as a control. Furthermore,
E-selectin is not expressed in HeLa cells used for analyses. The
PS-ONs were synthesized using conventional solid-phase triester
chemistry (Beaucage and Iyer, 1992). 29-Deoxy and 59-amino–mod-
ified phosphoramidites were purchased from commercial suppliers
(PerSeptive Biosystems, Framingham, MA; Glen Research, Sterling,
VA). The fluorophores were conjugated postsynthetically using
FITC or Texas Red Sulfonylchloride (Molecular Probes, Eugene, OR)
according to the manufacturer’s protocols. Free fluorophores were
separated from oligonucleotides by gel filtration using NAP-25
columns (Pharmacia, Piscataway, NJ).
Delivery of Oligonucleotides into Cells
PS-ONs were administered to cells by two methods. For lipofection
(Chiang et al., 1991) 0.25 mM PS-ON was combined with 10 mg/ml
Lipofectin (Life Technologies) in serum-free DMEM according to
the manufacturer’s protocol. Cells were washed twice with serum-
free DMEM and then incubated in the oligonucleotide/Lipofectin-
containing medium for 4 h. After lipofection, cells were washed
twice in complete medium and incubated for the indicated times,
but at least for 1 h in DMEM, 10% FBS before they were fixed. When
added to the medium without Lipofectin, the concentration of
PS-ON was 5 mM.
Using microinjection, 30 mM oligonucleotide with 6 mg/ml dex-
tran-Cascade Blue (Molecular Probes) in injection buffer (10 mM
NaH2PO4, 10 mM K2HPO4, 80 mM KCl, 4 mM NaCl, pH 7.2) was
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directly delivered into the cytoplasm or nucleus of cells. We used an
Eppendorff microinjector 5242 and micromanipulator 5170 setup
mounted on a Zeiss Axiovert 10 inverted microscope and self-made
microinjection needles. The needles were pulled on a Brown-Flam-
ing pipette puller (model P80, Sutter Instruments, San Francisco,
CA) from GC120TF-10 glass capillaries (Warner Instruments, Ham-
den, CT). The solutions to be injected were centrifuged for at least 30
min at 14,000 3 g at 4°C to remove any particulate material. One can
assume a 1:20 dilution of the concentrations in the needle upon
injection into the cell. In some experiments the PS-ONs were added
to permeabilized cells. Cells were permeabilized in CSK buffer
containing 0.5% Triton X-100 as described below and then incubated
in 0.2 mM PS-ON in CSK buffer lacking the detergent for 30 min at
37°C. Cells were rinsed twice in CSK without detergent and fixed.
Immunostaining and Fluorescence Microscopy
Cells were fixed for 15 min in PBS, 4% paraformaldehyde and then
washed for 5 min with PBS three times. If antibody staining was
involved, cells were permeabilized in PBS, 0.5% Triton X-100 for 5
min. After three washes for 5 min with PBS, cells were incubated for
30 min in primary antibody diluted in PBS, 1% normal goat serum.
Bound primary antibodies were detected with secondary antibodies
coupled to various fluorochromes (Jackson Immunoresearch, West
Grove, PA), again diluted in PBS, 1% normal goat serum, and
incubated for 30 min. Between the antibody incubations and after
the secondary reagent, cells were washed for 10 min in PBS three
times. Finally, the coverslips with the cells were mounted in 90%
glycerol in 0.2 M Tris-base (pH 8) containing 1 mg/ml p-phenyl-
enediamine. All incubations were carried out at room temperature.
Human ICAM-1 (CD54) protein was visualized with monoclonal
antibody 84H10 (Immunotech, Westbrook, ME). Primary antibodies
for colocalization studies of PS-ONs with known nuclear domains/
structures included mouse anti-SC35 (1:3000; Fu and Maniatis,
1990), mouse anti-U2-B0 (1:3; Habets et al., 1989), mouse anti-m3G
(1:5; Krainer, 1988), human anti-centromere (1:200; Moroi et al.,
1980), human anti-SM (1:600; gift from Joe Kraft, Yale University),
and mouse 5E10 anti-PML (1:3; Stuurman et al., 1992).
Images were acquired using a Nikon Microphot-FXA fluores-
cence microscope equipped with a Photometrics SenSys cooled
CCD camera (1,320 3 1,035 array, 6.7-mm pixel size, Photometrics,
Tucson, AZ) controlled by a Macintosh computer with Oncor Image
(Oncor, Gaithersburg, MD) software. For colocalization analysis, a
Zeiss confocal microscope LSM410 was used.
Nuclear Fractionation
HeLa cells grown on a glass coverslip in a 3.5-cm dish were lipo-
fected with fluorescently tagged PS-ONs as described above. The
coverslip was cut into four equal pieces. The first piece was fixed
immediately after lipofection. With the other pieces, nuclear frac-
tionation was carried out in three steps as described (Huang et al.,
1994). First, cells were incubated on ice for 10 min in CSK buffer (10
mM PIPES, pH 6.8, 3 mM MgCl2, 100 mM NaCl, 300 mM sucrose,
0.5% Triton X-100, 10 mM leupeptin, 2 mM vanadyl adenosine).
Then they were further extracted at 4°C for 5 min in extraction
buffer (10 mM PIPES, pH 6.8, 3 mM MgCl2, 250 mM ammonium
sulfate, 300 mM sucrose, 0.5% Triton X-100, 10 mM leupeptin, 2 mM
vanadyl adenosine). Finally, DNA was removed by treatment for
1 h at 37°C with 100 U/ml RQ-DNase (Promega, Madison, WI) in
CSK buffer containing 50 mM instead of 100 mM NaCl. After each
step of the fractionation, samples were quickly rinsed once in the
buffer used for the previous incubation, one coverslip piece re-
moved, and fixed in 4% paraformaldehyde in PBS as described
above. To check the deoxyribonuclease (DNase) digestion, cells
were stained for 5 min with 0.5 mg/ml DAPI (Molecular Probes).
RNase treatment was performed by substituting RQ-DNase with 0.4
mg/ml RNase A (Sigma Chemical, St. Louis, MO; boiled for 10 min
to destroy residual DNase in the preparation) and omitting vanadyl
adenosine in the buffer. The fractionated cells were incubated in
RNase A solution or buffer alone for 30 min at 37°C, rinsed twice in
CSK, 50 mM NaCl, and fixed.
Enzyme Immunoassay to Assess the Amount of
Oligonucleotides within Cells
A cell-based enzyme immunoassay was employed for comparative
measurements of PS-ONs in cells after the different steps of the
nuclear fractionation procedure or after the RNase treatment. HeLa
cells (5000) were seeded in each well of a 96-well plate; 2.5 d later,
0.25 mM fluorescein-conjugated PS-ON was introduced into cells by
means of 10 mg/ml Lipofectin as described above. Then nuclear
fractionation of the cells was performed in each well of the plate
using the same procedure as for cells on coverslips. At different
steps of the procedure a subset of wells was fixed with 4% parafor-
maldehyde in PBS. After fixation, all samples were washed with
PBS. Cells directly fixed without fractionation were permeabilized
with 0.5% Triton X-100 in PBS. All other samples were permeabil-
ized by the nuclear fractionation protocol. Unspecific binding sites
were blocked by incubation in PBS, 1% BSA, 0.02% Tween 20 (buffer
PBT) overnight at 4°C. Wells were washed with buffer PBT and
incubated with a monoclonal antibody against the fluorescein tag of
the PS-ONs (Boehringer Mannheim, Indianapolis, IN), diluted 1:60
in buffer PBT, for 2 h at room temperature. Wells were washed three
times, 10 min each, and then incubated with polyclonal sheep
anti-mouse IgG antibody conjugated with Peroxidase (Cappel/ICN,
Costa Mesa, CA) for 1 h at room temperature. After three 10-min
washes, peroxidase substrate o-phenylendiamine (Sigma-Fast tab-
lets, Sigma) was added. Finally, 30 min after substrate addition, the
absorbance of each well at 450 nm was measured with an EIA
reader (model 450; Bio-Rad, Hercules, CA). Control values of cells
that were not lipofected with oligonucleotides were subtracted from
the results. The means of six different wells per condition were
calculated and referred to the mean of the directly fixed cells, which
was set to 100%. In indirect immunofluorescence staining the anti-
FITC antibody detected a similar intracellular distribution of PS-
ONs, as observed with the fluorochrome-conjugated PS-ONs. There
was some higher cytoplasmic diffuse staining, and the contrast
between the PS foci and the diffuse nucleoplasmic molecules in the
nucleus was less pronounced.
Correlative Electron Microscopy (EM)
To analyze the ultrastructural features of phosphorothioate bodies
(PS bodies), we matched the pattern observed on the light micros-
copy level with the pattern of structures seen in the same cell on the
EM level. To that end we microinjected 60 mM PS-ON 11068-F
(conjugated to fluorescein) into the cytoplasm or nucleus of HeLa
cells growing on gridded coverslips (Bellco, Vineland, NJ). One
hour after injection, cells were fixed with 4% paraformaldehyde in
PBS and quickly examined under the Nikon FXA fluorescence mi-
croscope. Particular cells were photographed using the cooled CCD
camera (see above), and their position on the coverslip was regis-
tered by means of the grids. Then cells were fixed again in 3%
glutaraldehyde in 0.2 M cacodylate buffer, pH 7.4, for 45 min at
room temperature. The coverslips with the cells were washed in 0.2
M cacodylate buffer, pH 7.4, postfixed in 1% osmium tetroxide,
0.015% potassium ferro-cyanide for 1 h at room temperature, and
dehydrated through incubation in a series of ascending concentra-
tions of ethanol. Finally, the samples were embedded in Epon/
Araldite, and the glass was etched off with hydrofluoric acid. Re-
gions containing photographed cells were retrieved with the help of
the grids of the coverslips, which had been imprinted into the
Epon/Araldite plastic during embedding. Cells were serially sec-
tioned (80-nm sections), and the sections were counterstained with
2% uranyl acetate and Reynold’s lead citrate. The sections were
examined at 75 kV with a transmission electron microscope (H-7000,
Hitachi Scientific Instruments, Mountain View, CA). The same cell
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photographed at the light microscopy level was located, and the
section was identified and photographed that displayed a pattern of
structures corresponding to the PS bodies.
RESULTS
Correlation of Intracellular Distribution and
Antisense Activity
To simultaneously monitor antisense activity and
PS-ON distribution in single cells, we delivered fluo-
rescently tagged PS-ONs in the absence or presence of
cationic lipids to HeLa cells. Alternatively, PS-ONs
were microinjected into the cytoplasm or nucleus of
the cells. After induction of endogenous ICAM-1 ex-
pression with TNF-a, single-cell analysis of antisense
activity was performed by staining the treated cells
with an antibody against ICAM-1 (Figure 1). Loss of
the ICAM-1 signal indicated antisense activity. When
added to the medium without cationic lipids, the an-
tisense PS-ONs stayed trapped in vesicular structures
in the cytoplasm and did not show antisense activity
(Figure 1, A and B). In contrast, antisense PS-ONs
administered to cells by lipofection predominantly lo-
calized to the nucleus and inhibited the expression of
ICAM-1 protein (Figure 1, C and D). The concentra-
tion dependency of this antisense effect was evident
by comparing cells with strong or weak oligonucleo-
tide signals, i.e., high or low amounts of internalized
PS-ONs: a high amount of oligonucleotide coincided
with total loss of ICAM-1 protein staining in that cell
(Figure 1, C and D, arrow), whereas a low amount of
the antisense molecule still permitted the expression
of ICAM-1 protein (Figure 1, C and D, arrowhead).
When PS-ONs were microinjected into cells, the oligo-
nucleotide-containing cells displayed bright nuclear
fluorescence and strong repression of ICAM-1 protein
expression in comparison with surrounding nonin-
jected cells (Figure 1, E and F). Thus, in cells display-
ing antisense activity, PS-ONs localized predomi-
nantly to the cell nucleus. The nuclear distribution in
most cells consisted of numerous, bright spherical
structures (usually 20–30 per nucleus under the con-
ditions used), hereafter termed PS bodies, which were
set against a diffuse nucleoplasmic population (see
Figure 2 for a higher magnification). The nucleoli were
mostly free of PS-ON staining. This distribution re-
flected the situation 20 h after the delivery of the
PS-ONs to the cells, but it was also representative of
the distribution immediately after oligonucleotide de-
livery, e.g., after lipofection or nuclear microinjection,
and coincided with the distribution in living cells (our
unpublished results and Figure 8). A control PS-ON
without antisense activity against ICAM-1 that
reached the nuclear compartment showed a distribu-
tion indistinguishable from an active oligonucleotide
(Figure 1, G and H). We never detected any differ-
ences, within the resolution of the light microscope,
between the localization of active and control PS-ONs
or in the presence or absence of the endogenous target
RNA. We found the same pattern for all PS-ONs
tested irrespective of their sequence or the label and
means for detection (e.g., different fluorochromes, bi-
otin-tag, or use of an antibody against the PS-ON
itself; our unpublished results). Furthermore, the same
distribution was seen in cell types other than HeLa,
e.g., BHK, A549, IMR-90, Ref52, 3T3, or Rat-1 cells (our
unpublished results). In addition, the same nuclear
distribution pattern was obtained with antisense PS-
ONs against rat b-tropomyosin upon coinjection of
oligonucleotides and a plasmid-encoded target gene
(Lorenz and Spector, unpublished). With respect to
microinjection, there was no difference in the steady-
state distribution when the PS-ONs were injected into
the cytoplasm or the nucleus (our unpublished re-
sults). We also used polyethyleneimine as a transfec-
tion agent (Boussif et al., 1995) and found the same
distribution as with PS-ONs administered by cationic
lipids (our unpublished results). The mostly perinu-
clear vesicular staining in cells that received PS-ONs
with the help of Lipofectin (or polyethyleneimine) was
never seen upon microinjection and probably reflects
the uptake pathway through endocytotic compart-
ments and inefficient release of PS-ONs from endoso-
mal and/or lysosomal vesicles.
Relationship of PS Bodies to Known Nuclear
Structures and Antigens
To determine to which subnuclear structures the
PS-ONs might preferentially bind and to see
whether the PS bodies represented a known nuclear
domain, we used confocal microscopy to compare
the PS-ON pattern to various nuclear domains visu-
alized by specific antibodies. Figure 2 compares the
distribution of microinjected PS-ONs with the serine/
arginine protein splicing factor SC35, PML nuclear
bodies, or centromeres, respectively, which were
chosen because they also display foci in their distri-
bution. We did not find any accumulation of PS-
ONs at these sites nor were these antigens enriched
in the PS bodies. Occasional touching or overlap of
the PS bodies with SC35 was observed; however, we
think that this association is random and attributed
to the limited extrachromosomal space. The patterns
of the endogenous nuclear structures looked similar
in cells with or without oligonucleotides, suggesting
that the PS-ONs did not perturb nuclear architec-
ture. Other structures we found negative for PS-ON
accumulation were small nuclear ribonucleoprotein
particles (snRNPs), coiled bodies, DNA, DNA rep-
lication sites (visualized by bromodeoxyuridine in-
corporation as described in O’Keefe et al., 1992; our
unpublished results), and transcription sites (detect-
ed by in situ transcription using bromouridine
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triphosphate as described in Huang and Spector,
1996; our unpublished results). We also tested colo-
calization of PS-ONs with heterogeneous nuclear
ribonucleoproteins (hnRNPs) A1 and C, two dif-
Figure 1. Simultaneous evalu-
ation of PS-ON localization and
antisense activity. Fluorescein-
tagged antisense (4298-F) or
control (11721-F) PS-ONs were
delivered by different means to
HeLa cells. They were added to
the medium in the absence (A
and B, 4298-F; concentration 5
mM) or presence of Lipofectin
(C and D, 4298-F; at 0.25 mM), or
were directly microinjected (E
and F, 4298-F; G and H, 11721-F;
concentration in the injection
solution 30 mM). ICAM-1 ex-
pression was induced by TNF-a
for 18 h after the PS-ON deliv-
ery. The distribution of the PS-
ONs was monitored by means
of their fluorescence label (A, C,
E, and G), and ICAM-1 expres-
sion was detected by indirect
immunofluorescence micros-
copy (B, D, F, and H). When
trapped in the cytoplasm,
4298-F (A) did not show any ef-
fects on ICAM-1 expression (B).
In contrast, a predominant nu-
clear distribution of 4298-F (C
and E) coincided with strong
antisense activity (D and F). The
arrows or arrowheads point to
particular cells with high or low
PS-ON content and concomitant
low or high ICAM-1 protein
staining, respectively (C and D).
The control PS-ON 11721, de-
spite showing a similar nuclear
distribution as the antisense
molecule (G), did nevertheless
not display antisense effects (H).
Bar, 10 mm.
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fusely localized nucleoplasmic proteins. Both are
RNA-binding proteins, and A1 has been shown to
bind to oligoribonucleotides in vitro (Burd and
Dreyfuss, 1994; Abdul-Manan and Williams, 1996).
The diffuse localization of the two hnRNPs made it
difficult to assess accumulation in PS-ONs. How-
ever, at the sites of higher oligonucleotide concen-
tration, i.e., the PS bodies, there was never a higher
concentration of hnRNPs A1 and C (our unpub-
lished results). In conclusion, PS-ONs were not spe-
cifically attracted by, nor were PS bodies enriched
in, any known nuclear protein/structure, although
some degree of colocalization may exist due to the
diffuse nucleoplasmic distribution of the oligonu-
cleotides.
Characterization of the Formation of PS Bodies
As we did not find a known nuclear structure to
colocalize with the prominent PS bodies, the question
arises whether these sites reflected binding to un-
known nuclear structures or whether they were the
result of aggregation of PS-ON–containing complexes.
The formation of PS bodies was concentration depen-
dent. When treating HeLa cells in the presence of
Lipofectin with 10 nM PS-ON, only 14% of the cells
containing the oligonucleotides displayed PS bodies.
In contrast, addition of 50 nM or 250 nM PS-ON raised
this percentage to 28% or 86%, respectively. At the
same time, the number of PS bodies per cell increased.
In cells containing very high amounts of PS-ONs,
Figure 2. Colocalization analysis by confocal microscopy of PS-ONs 11068-F (A) or 12182-T (D and G) microinjected into HeLa cells and
three different nuclear structures, “speckles” enriched in splicing factor SC35 (B), PML nuclear bodies (E), and centromeres (H). The nuclear
domains were labeled with specific antibodies by indirect immunofluorescence. In all cases the PS-ONs did not accumulate at the respective
structures (see merge of the respective images in C, F, and I). Bar, 5 mm.
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thread-like structures were observed (our unpub-
lished results). The concentration dependency of for-
mation can also be seen in Figure 1C where some cells
with fainter fluorescence signals and thus lower oli-
gonucleotide content (e.g., the cell marked by the ar-
rowhead) do not display PS bodies. Since PS-ON sig-
nals in the nucleus could be observed in the absence of
PS bodies, these structures do not represent sites of
highest affinity for PS-ONs. PS bodies formed rapidly
within minutes after microinjection (our unpublished
results). Chilling of cells strongly reduced the forma-
tion of PS bodies by microinjected PS-ONs. Concen-
tration of PS-ONs in discrete foci was rarely observed,
and the typical PS body pattern was lacking even after
prolonged incubation of the injected cell on ice for 4 h
(Figure 3A). Furthermore, PS bodies did not form
upon nuclear injection of PS-ONs into formaldehyde-
fixed cells (Figure 3 B). Treatments of cells with
a-amanitin or 5,6-dichloro-1-b-d-ribofuranosylben-
zimidazole, either before or after administration of
PS-ONs, indicated that neither the formation nor the
persistence of PS bodies was dependent on ongoing
RNA polymerase II transcription (Figure 3C and our
unpublished results). ATP depletion of cells by treat-
ment with deoxyglucose and NaN3 did not abolish the
formation of PS bodies (our unpublished results).
These results argue that the formation of PS bodies is
concentration dependent, temperature sensitive, but
energy and transcription independent.
To determine whether two PS-ONs with different
sequences localize to the same PS body or accumulate
at distinct sites, we introduced the two molecules
conjugated with fluorescein or Texas Red, respec-
tively, independently of each other into HeLa cells.
The first PS-ON was microinjected into the cytoplasm,
and then the second PS-ON was added to the medium
complexed with cationic lipids. When such cells were
fixed and analyzed by confocal microscopy, the oligo-
nucleotides completely colocalized at each PS body
(Figure 4 A–C). No PS bodies were formed by the
second PS-ON alone, suggesting that additional
PS-ON molecules became attracted to the preexisting
PS bodies. When the first PS-ON was delivered to
living cells, e.g., using Lipofectin, and the second
PS-ON was added to permeabilized cells, these PS-
ONs bound to preexisting PS bodies as well (Figure 4,
D–F). However, in cells without preexisting PS bodies,
the PS-ONs added to the permeabilized cells were not
able to form PS bodies alone. They only displayed
granular signals (Figure 4, D–F, arrow). Similar results
were obtained in cells permeabilized with digitonin, a
procedure that retains more nuclear proteins than Tri-
ton X-100 permeabilization, and in other buffer sys-
tems (our unpublished results). These data are consis-
tent with the notion that the formation of the PS
bodies required activities and/or components of liv-
ing cells and that PS-ONs are not simply binding to
preexisting nuclear structures in cells.
PS Bodies at the Ultrastructural Level
Electron microscopy provides the means to detect nu-
clear substructures at high resolution. We performed
correlative fluorescence and electron microscopy on
HeLa cells injected with fluorescently tagged PS-ONs
and fixed to give optimal structural preservation. The
PS-ON patterns of individual cells were visualized by
fluorescence microscopy and photographed, after
which the same cells were processed for electron mi-
croscopy. The PS body pattern seen at the light micro-
Figure 3. Formation of PS bodies was restricted at 4°C, did not occur in fixed cells, and was independent of ongoing RNA-polymerase II
transcription. (A) HeLa cells were chilled for 30 min on ice, injected quickly within about 2 min with the PS-ON, and incubated for another
4 h on ice until they were fixed. (B) HeLa cells were fixed and washed and then injected with the PS-ON. (C) HeLa cells were treated for 4 h
with 50 mg/ml a-amanitin and then injected with the PS-ON. After another 30 min in the presence of the drug, cells were fixed and stained
with antibody against SC-35 to check for the effects of transcription inhibition (SC-35 staining not shown). The noticeable changes of brighter
PS-ON signals around the reorganized nucleoli are very likely the result of the nuclear reorganization induced by transcription inhibition
(Haaf and Ward, 1996). In all cases, 30 mM PS-ON 11068-F was used for injection. Bar, 5 mm.
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scope level (Figure 5C) was recognizable in the elec-
tron microscope sections (Figure 5, A and B). The PS
bodies were characterized as 150–300 nm in diameter,
electron-dense, homogenous spherical nuclear bodies
without obvious substructures. This appearance was
clearly different from the ultrastructure of coiled bod-
ies and PML bodies (Brasch and Ochs, 1992; Stuurman
et al., 1992; Koken et al., 1994; Bohmann et al., 1995).
Interestingly, nuclear bodies of the same size and sim-
ilar morphology were also present in cells without
PS-ONs, although their number was much lower (Fig-
ure 5, D and E). This raised the possibility that PS-ON
induced the formation of a certain kind of nuclear
body. However, there was no indication that the pres-
ence of the PS-ONs at the concentration used per-
turbed nuclear architecture.
PS-ONs Associate with the Nuclear Matrix
We analyzed how tightly the PS-ONs were bound to
nuclear structures. To this end we performed in situ
fractionation, which consisted of a series of treatments
of unfixed cells that remove soluble fractions and
DNA-attached components to obtain the nuclear ma-
trix fraction (Fey et al., 1986). Fluorescently tagged
PS-ONs were administered into HeLa cells by means
of cationic lipids; the cells were subsequently treated
with buffer containing Triton X-100, and then high salt
buffer, and finally cells were incubated with DNase I
Figure 4. Two different PS-ONs introduced into cells independently of each other colocalize at the same nuclear structures. (A–C) Both
PS-ONs were administered into living cells; 12182-T (A) was microinjected and then 11068-F (B) was delivered with the help of cationic lipids.
All foci seen with 12182-T were also occupied by 11068-F. (D–F) 12182-T (D) was introduced into living cells by means of cationic lipids. Then
cells were permeabilized and incubated with 11068-F at 37°C in vitro (E). In vitro administered 11068-F bound to PS bodies preformed by
12182-T but failed to display such structures in cells without such bodies preformed in the living state. Analysis by confocal microscopy with
panels C and F representing merges of images A and B or D and E, respectively. The arrowheads point to particular PS bodies; the arrow
marks the cell which has no PS bodies. Bar, 5 mm.
Figure 5 (facing page). (A–C) On the ultrastructural level PS bod-
ies were electron-dense, 150–300 nm in diameter, spherical nuclear
bodies without apparent substructure. HeLa cells injected with
11068-F were fixed, photographed under epifluorescence to record
the PS-ON signals, and processed for transmission electron micros-
copy under conditions that optimally preserve ultrastructure. Then
thin sections were prepared from the injected cells. By matching
patterns of PS bodies of the fluorescence image with patterns of
structures seen on an EM section of the same cell, the PS bodies in
the EM image were identified. The arrows point to four PS bodies
displaying a characteristic pattern in the EM image of a 80-nm
section (A), a higher magnification of the region of the same section
(B), and the fluorescence photomicrograph of the same cell (C). (D
and E) The ultrastructure of a control nucleus revealed spherical
bodies (arrows) similar in appearance to PS bodies. Transmission
electron micrograph showing a nucleus of a HeLa cell (D) and an
enlargement of two nuclear bodies of the same cell (E), which had
not been injected with PS-ONs but was grown on the same coverslip
as the injected cells. Bars, 1 mm.
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to remove the DNA. At each step a sample was fixed,
and images of the PS-ON signal were acquired by
fluorescence microscopy (Figure 6, A, C, and E).
Throughout the whole procedure the PS-ON distribu-
tion was not altered. There were no striking differ-
ences in the levels of fluorescence of the PS-ON in the
nucleus during fractionation. To compare the amount
of the remaining oligonucleotides in a more quantita-
tive manner, we performed an indirect enzyme immu-
noassay (see MATERIALS AND METHODS) with an-
tibodies against the fluorescein tag of the PS-ONs
(Figure 7A). We measured an initial gain of signal
between the directly fixed cells and the fractions, but
within the fractions there were only small differences.
The slight decreases in the signals were probably due
to some cell loss during the procedure. The lower
values of the directly fixed cells were likely caused by
reduced accessibility to the oligonucleotides for the
antibodies in comparison with extracted cells. When
treated with RNase A instead of DNase, a significant
amount of the PS-ONs in the nucleoplasm was re-
moved (Figure 6, compare G with H). In contrast, the
PS bodies appeared to be mostly inert against the
action of RNase A. The loss of oligonucleotides was
clearly evident when measured by enzyme immuno-
assay (Figure 7B). Our results imply that the majority
of PS-ON molecules bind to components of the nu-
clear matrix and that PS bodies are resistant to both,
DNase or RNase A.
Dynamics of PS Bodies
To determine whether PS bodies are static or mobile
structures, we observed their distribution in living
cells over time. We observed the distribution of a
fluorescently tagged PS-ON in a single cell by time
lapse microscopy keeping particular PS bodies in fo-
cus throughout the experiment. Over 6.5 h, the PS
body pattern was unchanged, the number of foci was
the same, and individual PS bodies did not signifi-
cantly change their location with respect to each other
and, for example, nucleoli (Figure 8). In addition, there
was no noticeable increase in cytoplasmic signal. This
suggested that PS bodies were rather immobile, stable
structures and that during the observed time interval
there was neither disintegration nor de novo forma-
tion.
To follow the fate of PS-ONs during mitosis, PS-
ONs were delivered into interphase cells, either by
microinjection or by lipofection, and their distribution
was analyzed 6–12 h thereafter. During mitosis, PS-
ONs were distributed throughout the mitotic cyto-
plasm with exclusion of the chromosomes (Figure 9, B
and D). In addition, in metaphase, anaphase, or telo-
phase cells, bright spherical foci of accumulated mol-
ecules were observed (Figure 9, B and D, arrowheads).
As these structures were fewer in number than the PS
bodies in interphase cells (compare numbers of PS
bodies per nucleus in Figure 9A with 9B and 9D), they
Figure 6. Nuclear fractionation suggested that the majority of
intranuclear PS-ONs resided at the nuclear matrix as the nuclear
binding was resistant to detergent, salt, and DNase but not to RNase
treatment. HeLa cells lipofected with 0.25 mM PS-ON 11068-F were
either directly fixed (A) or underwent consecutive treatments with
CSK buffer containing 0.5% Triton X-100 (B), extraction buffer con-
taining high salt concentration (C and D) and DNase (E and F)
before they were fixed. DAPI staining verified the digestion of the
DNA (D vs. F). Cells were also treated with buffer alone (G) or
RNase A (H) instead of DNase. Epifluorescence images of the oli-
gonucleotide signals (A–C, E, G, and H) and DNA signals (D and F)
were taken from samples of the same lipofection and were acquired
and processed in the same manner for panels A–C and E; panels D
and F; panels G and H. Bar, 5 mm.
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were probably made up of several PS bodies fused to
each other. Indeed, electron microscopy revealed that
these large foci coincided with 500–600 nm in diam-
eter, electron-dense bodies that were morphologically
indistinguishable from interphase PS bodies (our un-
published results). However, we cannot exclude that
some PS bodies might have disintegrated. We fol-
lowed a single anaphase cell loaded with PS-ONs
through completion of mitosis and entry into the next
cell cycle and found that the oligonucleotides reen-
tered the newly formed daughter nuclei (Figure 9, J
and K). The reentry of the PS-ONs into the daughter
nuclei was later than the reentry of the nucleolar pro-
tein fibrillarin, but earlier than the reentry of
Figure 7. Comparative measurements of cell-based PS-ONs by indirect enzyme immunoassay corroborated the binding of a major amount
of the oligonucleotides to the nuclear matrix. (A) HeLa cells grown in 96-well plates were lipofected with 0.25 mM 11068-F, fixed directly
(fixed) or fractionated consecutively with CSK buffer (CSK), extraction buffer (high salt), and DNase (DNase). There was little loss during
fractionation. (B) Experiment in which the DNase step had been substituted with buffer alone (buffer) or RNase A (RNase). RNase treatment
resulted in a strong displacement of PS-ONs from the nuclear remnants. The values represent the means 6 SD of six wells of a representative
experiment corrected for the means obtained for cells that had not been lipofected with oligonucleotide. They were normalized against the
mean obtained for directly fixed cells (A) or buffer-treated cells (B), which was set at 100%. Similar results were obtained with a different
PS-ON.
Figure 8. PS-ON patterns were stable over a period of 6.5 h. HeLa cells received 0.25 mM PS-ON 11068-F complexed to Lipofectin. Six hours
after lipofection time-lapse microscopy of living cells was started and fluorescence images were taken at the indicated times from the same
two cells. The arrowheads point to three particular PS bodies in the nucleus that were held in focus throughout the experiment. Their location
with respect to each other and to other nuclear structures like the nucleoli did not change noticeably. Note that apparent changes in the PS
body pattern, especially in the upper cell, are solely due to focus changes caused by the movements of the cell, e.g. rotations of the nucleus.
Bar, 5 mm.
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hnRNP-A1 (our unpublished results). The bright mi-
totic foci apparently stayed behind in the cytoplasm
(Figure 9, F, J, and K, arrowheads) where they de-
creased in brightness over time until they dissap-
peared. This can either be explained by a late move-
ment of oligonucleotide molecules from the foci into
the daughter nuclei or degradation in the cytoplasm.
PS bodies in the daughter nuclei were not evident
until the cells were well into G1 (Figure 9, F and K,
arrows). Thus, their formation apparently occurred de
novo from the diffuse PS-ON pool.
DISCUSSION
It is important to know the cellular pharmacokinetics
of a compound intended for clinical use with respect
to its specific and also its unspecific effects. Here we
have demonstrated that, under conditions of specific
antisense activity against ICAM-1, the predominant
localization of PS-ONs was nuclear. This was un-
equivocally demonstrated by the simultaneous single
cell analysis of PS-ON antisense activity and distribu-
tion. Since localization of a control PS-ON without
antisense effect was indistinguishable from an active
molecule, this distribution cannot be considered caus-
ally related to specific antisense activity. Nevertheless,
the nuclear localization after administration of PS-
ONs can serve as an indicator that the oligonucleo-
tides escaped their trapping in vesicular structures in
the cytoplasm, which has been suggested to be re-
sponsible for failure to detect significant antisense ef-
fects (Bennett et al., 1992; Wagner et al., 1993). Further-
more, the predominant nuclear localization of PS-ON
molecules argues that the potential of the phosphoro-
thioate modification as a drug for specific activity, but
also side-effects, is greater in the nucleus. Even in
cases where the antisense molecule acts in the cyto-
plasm, it might actually hybridize to its target in the
nucleus and be exported complexed to RNA (Baker et
al., 1997).
The PS-ON localization sites in the nucleus con-
sisted of numerous bright spherical structures desig-
nated PS bodies and a diffuse nucleoplasmic popula-
tion excluded from the nucleoli. Similar distributions
of PS-ONs have been observed previously in studies
that did not simultaneously measure antisense activity
(Chin et al., 1990; Bennett et al., 1992; Fisher et al., 1993;
Nestle et al., 1994; Shoeman et al., 1997). Under our
experimental conditions, we have no evidence for sig-
nificant damage to the organization of the nucleus on
the light and electron microscopy level after introduc-
tion of PS-ONs. Also, DNA replication and in situ
transcription using bromodeoxyuridine or bromouri-
dine triphosphate, respectively, were similar to con-
trol cells (our unpublished results). The nuclear distri-
bution was similar for all PS-ONs analyzed
irrespective of their sequence or of the means used for
their detection, e.g., fluorescence tag or indirect stain-
ing with an antibody. It was also similar immediately
after nuclear injection or minutes after cytoplasmic
injection and in living cells up to at least 6.5 h after
Figure 9. PS-ONs during mitosis. PS-ONs were excluded from the
chromosomes but otherwise dispersed throughout the mitotic cyto-
plasm. Typical PS bodies (arrows) were not observed in mitotic
cells, but fewer and larger foci (arrowheads) were present, which
stayed behind the diffusely distributed material with respect to
reentry into the daughter nuclei. PS bodies formed late when most
of the PS-ON molecules were already nucleoplasmic and the cell
was already well into G1 phase. Interphase HeLa cells were injected
with 30 mM 11068-F and fixed 2 h later (A–G). To display all PS-ON
foci in a cell, confocal z sections throughout the cell were taken and
projected on top of each other. Shown are three interphase cells (A),
a metaphase (B), a late anaphase (D), and G1 phase (F) cells, the last
three identified by their respective Nomarski images (C, E, and G).
Time-lapse epifluorescence microscopy of a HeLa cell lipofected
with PS-ON 11068-F following it from anaphase through comple-
tion of mitosis and entry into G1 phase of the next cell cycle (H–K).
Bars, 5 mm.
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administration, arguing that what we observed re-
flected mostly full-length oligonucleotides at their lo-
cation within live cells. Consistent with that sugges-
tion, stability measurements of PS-ONs delivered with
liposomes into tissue culture cells have shown about
80% intact PS-ONs after 6 h and about 70% intact
molecules 1 d after delivery (Thierry and Dritschilo,
1992).
PS Bodies, Nuclear Structures Formed by PS-ONs
The formation of the PS bodies, which represent the
sites of highest PS-ON accumulation in the nucleus, do
not coincide with known nuclear structures, and none
of the investigated nuclear antigens were accumulated
at these sites. We found the formation of PS bodies to
be characteristic of the phosphorothioate modification.
A phosphodiester oligonucleotide of the same se-
quence with 29-O-propyl ribose moieties for nuclease
stability never displayed such a structure (our unpub-
lished results). Furthermore, oligonucleotides of other
modifications that contained phosphorothioate inter-
nucleoside bridges (e.g., 29-O-methoxyethyl-PS-ONs
or 29-F-PS-ONs) show PS bodies as well and colocalize
with PS bodies formed by plain PS-ONs (Lorenz,
Baker, Bennett, and Spector, unpublished). PS bodies
have also been observed in previously published re-
ports (Chin et al., 1990; Bennett et al., 1992; Fisher et al.,
1993; Shoeman et al., 1997). In contrast to the present
study, none of these reports provided a detailed char-
acterization of these structures. The concentration de-
pendency of the formation of PS bodies argues that
they might result from aggregation of PS-ONs or PS-
ON–containing complexes. However, several lines of
evidence suggest that the formation of PS bodies is not
simply a random self-aggregation process but requires
the environment of a living cell for its induction: first,
PS bodies were not observed upon delivery of PS-ONs
to fixed or permeabilized cells. Second, even after
prolonged incubation at 4°C, the typical PS body pat-
tern was lacking. Third, on the ultrastructural level PS
bodies resemble nuclear bodies that can be found,
notably with less frequency, in control cells in the
absence of PS-ONs. Fourth, the PS bodies show dy-
namic changes during mitosis and then form de novo
in the newly assembled daughter nuclei. Thus, it is
likely that PS bodies formed de novo once a certain
concentration was exceeded and that this event takes
place only in intact cells with all their components and
activities.
Once formed, existing PS bodies appear to act as
nucleation sites for additional PS-ONs, even mole-
cules delivered to permeabilized cells. This also pro-
vides the explanation for the colocalization of two
PS-ONs, delivered independently into living cells, at
each PS body. Since the formation of the PS bodies
occurred very quickly and in ATP-depleted cells, any
cellular components involved are likely to already be
present in the nucleus and more time-consuming pro-
cessing steps or metabolic energy for the assembly of
the PS bodies do not appear to be required.
The composition and function of nuclear bodies are
poorly defined (Brasch and Ochs, 1992). Our results
showed that PS bodies neither colocalize nor structur-
ally coincide with coiled or PML bodies, two of the
better characterized nuclear bodies. The PS bodies
appear to fit most closely into the class of simple
nuclear bodies (Chaly et al., 1983; Brasch and Ochs,
1992). Coiled and PML bodies have been shown to
respond to cell cycle, metabolic status, transformation,
or viral infection by changes in their composition,
increased formation, or disintegration (Spector et al.,
1992; Andrade et al., 1993; Ochs et al., 1995; Terris et al.,
1995; Ishov and Maul, 1996; Ahn and Hayward, 1997).
In contrast, we have no evidence for significant differ-
ences in the number and pattern of PS bodies in qui-
escent versus cycling or in primary versus trans-
formed cells (our unpublished results). In addition, we
did not find snRNPs or nucleolar antigens to be en-
riched in PS bodies as in the case of coiled bodies
(Bohmann et al., 1995). PS bodies share some simi-
larities in their behavior during mitosis with PML or
coiled bodies: with respect to their presence in mi-
totic cells, PS bodies behave similarly to PML bodies
(Stuurman et al., 1992). However, considering that
PS bodies apparently assembled de novo in the
daughter nuclei from the diffusely localized mole-
cules, in that respect they behaved in a similar man-
ner to coiled bodies that reassemble in G1 phase
(Brasch and Ochs, 1992; Bohmann et al., 1995). Ex-
clusion of larger particles from reentry into the
daughter nuclei has also been observed for the splic-
ing factor SC-35 (Spector et al., 1991), the meaning of
which is unknown.
One possible explanation for the accumulation of
PS-ONs in PS bodies is a reaction of a cell to sequester
an overload of stable oligonucleotide to render it un-
able to exert toxic effects. The formation of nuclear
bodies might also be coupled to the degradation of
PS-ONs. The disappearance of the large mitotic
PS-ON foci in the cytoplasm of G1 phase cells could
reflect one such degradation pathway. It will be useful
to identify host cell factors required for the formation
of PS bodies. One might find at these sites oligonucle-
otide-metabolizing activities, such as nucleases, which
are still ill-defined on the molecular level and with
respect to their specific cellular location. Sequestration
in PS bodies might limit the amount of free or loosely
bound PS-ON available for hybridization to the target
RNA or, on the contrary, might provide a depot of
antisense molecules where PS-ONs are bound through
relatively low-affinity interactions in comparison with
the high affinities displayed toward their target se-
quences in the RNA. Such depot effects have been
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suggested to be one explanation for the unaffected
potencies of C-5 propyne PS-ONs upon changes in the
levels of expressed target RNA (Flanagan et al., 1996).
Another possibility is that small cationic molecules,
such as the polyamines spermine and spermidine,
play a role in binding PS-ONs and forming PS bodies.
Polyamines have been localized to the cell nucleus by
light and electron microscopy and are implicated in
the condensation of chromatin (Hougaard, 1992; Roch
et al., 1997 and references therein). However, interac-
tions between PS-ONs and polyamines have not been
investigated so far. Coinjection of a 100-fold excess of
spermine and spermidine over a PS-ON did not result
in any noticeable redistribution of the oligonucleotides
or change of the PS body structures (our unpublished
results). In addition, coinjection of 20 mM of a poten-
tially competing polyanion, heparin, did not abolish
formation of PS bodies (our unpublished results). It
will be interesting to determine whether PS bodies are
formed in vivo in the tissues of an organism treated
with PS-ONs as well.
PS-ONs Are Associated with the Nuclear Matrix
The nuclear pools of PS-ONs were found to bind to the
nuclear matrix, which is operationally defined as the
nuclear remnants persisting after removal of DNA
and loosely bound nuclear components (Berezney,
1991). It consists of a peripheral component made up
of the nuclear lamina and an internal matrix including
residual nucleoli and an RNP network. As most
PS-ON molecules were resistant to the removal of
loosely attached material and DNA, associating pro-
teins likely have to be sought in this fraction. The
internal nuclear matrix is made up of proteins and
RNA. The latter explains why RNase treatment ex-
tracts nuclear matrix material. RNase treatment also
displaced most of the bound PS-ON with the notice-
able exception of the PS body-bound molecules.
Therefore, it is likely that PS-ONs are directly or indi-
rectly bound to an RNP. In contrast, PS bodies appear
to be tightly bound to the nuclear matrix indepen-
dently of RNA, or RNase may not be accessible to
these nuclear structures. Among the most abundant
nuclear matrix proteins are hnRNPs (Mattern et al.,
1996). Many proteins, however, have been found in
the nuclear matrix fraction, and many nuclear func-
tions such as transcription and DNA replication and
splicing are thought to be linked to it (Berezney, 1991).
Among the proteins/complexes we analyzed for co-
localization with the PS-ONs were SC-35, snRNPs,
hnRNP-A1, and hnRNP-C, all of them known to be
associated with the nuclear matrix. The serine/arginine
protein-splicing factor SC-35 and snRNPs are both
found in “speckles” (Spector, 1993). In contrast, PS-
ONs never showed a “speckled” pattern. It has been
argued previously that there is some degree of overlap
between snRNPs and PS-ONs (Chin et al., 1990; Shoe-
man et al., 1997), but when we used four different
antibodies to antigens in “speckles,” we clearly saw no
enrichment of PS-ON at these structures. In the other
studies, higher concentrations of PS-ONs than used
here were injected, which might influence the results.
hnRNPs A1 and C are both diffusely localized in the
nucleoplasm, and therefore their signals colocalize
with the diffuse PS-ON signals. At the sites of higher
PS-ON concentration, however, i.e., the PS bodies, we
never detected higher concentrations of hnRNPs. Two
other observations also speak against a stable associ-
ation of hnRNP-A1 and PS-ONs. Upon transcription
inhibition, the shuttling of hnRNP-A1 is inhibited and
the A1 molecules become trapped in the cytoplasm
(Pin˜ol-Roma and Dreyfuss, 1992), a phenomenon we
did not observe for PS-ONs (our unpublished results).
Also, reentry into newly formed daughter nuclei oc-
curred earlier for PS-ONs than for hnRNP-A1 (our
unpublished results). However, there are many other
possible proteins in nuclear matrix fractions that
might have affinities for oligonucleotides. If a PS-ON–
interacting molecule is diffusely localized or PS-ONs
bind to a vast variety of different nuclear molecules, it
would also prevent us from observing complexes be-
tween PS-ONs and particular antigens by fluorescence
microscopy. A number of proteins have been cross-
linked to PS-ONs that have been added to isolated
nuclei (Leonetti et al., 1991), and two categories of
high- and low- affinity binding sites totaling about 6
million per cell nucleus have been postulated (Clarenc
et al., 1993). Others have found a high extent of com-
plex formation between PS-ONs and nuclear proteins
in gel shift assays (Brown et al., 1994). However, no
protein has been identified, and the result might not
reflect the in vivo situation. Many PS-ON–binding
proteins thus far identified are cell surface molecules
(reviewed by Stein, 1996). One exception is the pre-
dominantly nucleolar protein nucleolin, which binds
PS-ONs in vitro (Weidner et al., 1995). However, we
did not usually find PS-ONs within the nucleolus.
Only when the nucleoplasm was saturated with high
amounts of oligonucleotides did some overlap with
nucleolar proteins occur at the nucleolar borders (our
unpublished results).
Taken together, our results provide more insight
into the spatial and temporal distribution of PS-ONs
in the nucleus under conditions at which specific an-
tisense activity can occur. We have characterized a
nuclear structure that was formed after PS-ONs were
introduced into the cell and that may be involved in
sequestering oligonucleotides. Clearly, more has to be
learned about the cell biology of antisense compounds
to make this approach a true rational drug design. The
questions where exactly antisense molecules hybridize
to their target, what determines accessibility for this
hybridization, what is the fate of the oligonucleotide/
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target RNA hybrid and where and through what
mechanisms the antisense activity is actually exerted
are all largely unanswered on the molecular level.
Furthermore, many intracellular factors which interact
with the phosphorothioate modification remain to be
identified.
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